Alnylam Pharmaceuticals Executive and Leadership Team

Yvonne Greenstreet, the Chief Executive Officer at Alnylam Pharmaceuticals, directs the company's overall strategy and operational execution. Greenstreet guides the advancement of Alnylam's innovative RNA interference therapeutics, focusing on bringing novel treatments for rare genetic, cardio-metabolic, and hepatic infectious diseases to market. Overseeing the development pipeline, Greenstreet ensures alignment with the company's mission to establish a new class of medicines. This leadership role involves driving research and development initiatives, fostering strategic partnerships, and managing investor relations to support long-term growth and patient impact. By championing scientific rigor and commercial excellence, Yvonne Greenstreet positions Alnylam Pharmaceuticals at the forefront of biopharmaceutical innovation, translating complex science into tangible therapeutic solutions for unmet medical needs globally.

Jeffrey Poulton, the Chief Financial Officer at Alnylam Pharmaceuticals, manages the company's financial operations, capital allocation, and long-term financial planning. Poulton oversees all aspects of financial reporting, treasury, and investor relations, ensuring fiscal responsibility and strategic resource deployment. This critical role involves guiding Alnylam's financial strategy to support its robust pipeline of RNAi therapeutics and commercial product launches. By optimizing financial performance and managing risk, Jeffrey Poulton enables the company to invest in groundbreaking research and development, driving innovation in rare genetic, cardio-metabolic, and hepatic infectious diseases. Poulton's leadership ensures Alnylam Pharmaceuticals maintains a strong financial foundation to achieve its mission of delivering transformative medicines to patients worldwide.

Martin Schmieg, the Senior Vice President & Chief Financial Officer at Alnylam Pharmaceuticals, supports the company's financial strategy and operational management. Schmieg contributes to the oversight of financial planning, budgeting, and resource allocation, ensuring alignment with Alnylam's strategic objectives in developing and commercializing RNAi therapeutics. This role involves close collaboration with the Chief Financial Officer and other executive leaders to maintain financial discipline and support the company's growth initiatives. By managing key financial processes, Martin Schmieg aids in the advancement of Alnylam Pharmaceuticals' pipeline, focusing on delivering innovative treatments for rare genetic, cardio-metabolic, and hepatic infectious diseases. Schmieg's contributions are vital to sustaining the company's financial health and its commitment to patient well-being.

Shweta Randeria, the Chief Marketing Officer at Alnylam Pharmaceuticals, spearheads all global marketing strategies and commercial operations. Randeria drives the market positioning and patient access initiatives for Alnylam's portfolio of RNAi therapeutics, including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. Overseeing brand development and product launches, Randeria ensures effective communication of the therapeutic benefits to healthcare providers and patient communities. This executive function involves analyzing market trends, identifying growth opportunities, and developing innovative campaigns to expand patient reach. By collaborating closely with research, development, and sales teams, Shweta Randeria ensures that Alnylam's groundbreaking treatments reach the patients who need them most, reinforcing the company's commitment to transforming lives through advanced RNAi technology.

Vasant Jadhav, the Chief Technology Officer at Alnylam Pharmaceuticals, directs the company's technological infrastructure and innovation strategy. Jadhav oversees the development and implementation of advanced technology solutions that support Alnylam's research, development, and manufacturing processes for its RNAi therapeutics. This executive responsibility includes managing data science initiatives, ensuring robust cybersecurity measures, and exploring emerging technologies to enhance operational efficiency and scientific discovery. By driving technological advancements, Vasant Jadhav enables Alnylam Pharmaceuticals to accelerate the development of novel treatments for rare genetic, cardio-metabolic, and hepatic infectious diseases. Jadhav's focus on cutting-edge technology is integral to the company's mission of translating scientific breakthroughs into life-changing medicines.

Elizabeth Bailey, the Senior Executive Assistant To Chief Human Resources Officer at Alnylam Pharmaceuticals, provides comprehensive administrative and operational support to the Chief Human Resources Officer. Bailey manages critical functions that facilitate the smooth operation of the human resources department, ensuring efficient workflow and effective communication. This role involves coordinating executive schedules, managing correspondence, and supporting key HR initiatives aimed at fostering a positive and productive work environment. By ensuring seamless administrative processes, Elizabeth Bailey directly contributes to the strategic goals of Alnylam Pharmaceuticals, supporting the development and retention of its talented workforce. Bailey's dedication enhances the HR team's capacity to drive employee engagement and organizational success.

Melissa McLaughlin, the Chief Human Resources Officer at Alnylam Pharmaceuticals, leads the company's human capital strategy and organizational development. McLaughlin oversees all aspects of human resources, including talent acquisition, employee relations, compensation, and benefits, ensuring Alnylam cultivates a high-performing and engaged workforce. This executive function is crucial for supporting the company's rapid growth and its mission to develop innovative RNAi therapeutics. By fostering a culture of collaboration and innovation, Melissa McLaughlin attracts and retains top talent essential for advancing treatments for rare genetic, cardio-metabolic, and hepatic infectious diseases. McLaughlin's leadership ensures Alnylam Pharmaceuticals remains an employer of choice, driving success through its people.

Danielle Dougherty, the Manager, Chief Marketing Officer Management at Alnylam Pharmaceuticals, supports the strategic execution and operational efficiency of the marketing department. Dougherty assists in managing key marketing projects and initiatives, ensuring alignment with the overall commercial strategy for Alnylam's RNAi therapeutics. This role involves coordinating cross-functional efforts and facilitating communication between the marketing team and other departments. By providing dedicated management support, Danielle Dougherty contributes to the successful implementation of marketing plans designed to reach patients and healthcare providers. Dougherty's efforts enhance the effectiveness of Alnylam Pharmaceuticals' market outreach, supporting the company's mission to deliver life-changing medicines.

Matthew Dowling, the Manager, Chief Marketing Officer Management at Alnylam Pharmaceuticals, plays a key role in executing marketing strategies and managing departmental operations. Dowling supports the Chief Marketing Officer in overseeing product launches and market development activities for Alnylam's portfolio of RNAi therapeutics. This position involves coordinating marketing campaigns, analyzing market data, and ensuring seamless execution of commercial plans. By driving operational excellence within the marketing function, Matthew Dowling contributes to expanding patient access to innovative treatments for rare genetic, cardio-metabolic, and hepatic infectious diseases. Dowling's management ensures Alnylam Pharmaceuticals effectively communicates its scientific advancements and therapeutic value.

Robert Hesslein, the Chief Legal Officer at Alnylam Pharmaceuticals, oversees all legal affairs and ensures regulatory compliance across the organization. Hesslein manages the company's legal strategy, intellectual property portfolio, and corporate governance, safeguarding Alnylam's interests as it develops novel RNAi therapeutics. This executive responsibility includes advising on complex legal matters related to drug development, clinical trials, and commercialization. By providing expert legal counsel, Robert Hesslein supports Alnylam Pharmaceuticals' mission to bring groundbreaking treatments for rare genetic, cardio-metabolic, and hepatic infectious diseases to patients. Hesslein's leadership ensures the company operates with the highest ethical and legal standards, fostering trust and integrity.